

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Changes in IgE sensitization and total IgE levels over 20 years of follow-up

### This is the author's manuscript

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1528216> since 2016-06-08T11:23:15Z

*Published version:*

DOI:DOI: <http://dx.doi.org/10.1016/j.jaci.2015.09.037>

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



# UNIVERSITÀ DEGLI STUDI DI TORINO

***This is an author version of the contribution published on:***

*[Journal of allergy and clinical immunology, vol. 137, issue 6, 2016, DOI:  
10.1016/j.jaci.2015.09.037]*

***The definitive version is available at:***

<http://www.sciencedirect.com/science/article/pii/S009167491501430X>

Manuscript Number:

Title: Changes in IgE sensitisation and total IgE over 20 years of follow-up

Article Type: Original Article

Section/Category: Original Article - Other

Keywords: Allergens; sensitisation; cohort study; epidemiology; immunoglobulin E; longitudinal analysis; aging; immunosenescence

Corresponding Author: Dr. André F S Amaral, PhD

Corresponding Author's Institution: Imperial College London

First Author: André F S Amaral, PhD

Order of Authors: André F S Amaral, PhD; Roger B Newson, DPhil; Michael Abramson, PhD; Josep M Antó, PhD; Roberto Bono, PhD; Angelo G Corsico, PhD; Roberto de Marco, PhD; Pascal Demoly, MD; Bertil Forsberg, PhD; Thorarinn Gislason, PhD; Joachim Heinrich, PhD; Ismael Huerta, MD; Christer Janson, PhD; Rain Jõgi, PhD; Jeong-Lim Kim, PhD; José Maldonado, MD; Jesús Martínez-Moratalla Rovira, MD; Catherine Neukirch, MD; Dennis Nowak, MD; Isabelle Pin, MD; Nicole Probst-Hensch, PhD; Chantal Raherison-Semjen, PhD; Cecilie Svanes, PhD; Isabel Urrutia Landa, PhD; Ronald van Ree, PhD; Serge A Versteeg, BSc; Joost Weyler, PhD; Jan-Paul Zock, PhD; Peter G Burney, MD; Deborah L Jarvis, MD

Manuscript Region of Origin: UNITED KINGDOM

**Abstract:** Background: Cross-sectional studies have reported a lower prevalence of sensitisation in older adults, but few longitudinal studies have examined whether this is an aging or a year-of-birth cohort effect.

**Objective:** To assess changes in sensitisation and total IgE in a cohort of European adults as they aged over 20-year period.

**Methods:** Serum specific IgE to common aeroallergens (house dust mite, cat, grass) and total IgE were measured in 3206 adults, from 25 centres in the European Community Respiratory Health Survey, on three occasions over 20 years. Changes in sensitisation and total IgE were analysed by regression analysis, corrected for potential differences in laboratory equipment, and using inverse sampling-probability weights to account for non-response.

**Results:** Over the 20-year follow-up, the prevalence of sensitisation to at least one of the three allergens fell from 29.4% to 24.8% (-4.6%, 95%CI: -7.0% to -2.1%). The prevalence of sensitisation to house dust mite (-4.3%, 95%CI: -6.0% to -2.6%) and cat (-2.1%, 95%CI: -3.6% to -0.7%) fell more than sensitisation to grass (-0.6%, 95%CI: -2.5% to 1.3%). Age-specific prevalence of sensitisation to house dust mite and cat did not differ between year-of-birth cohorts, but sensitisation to grass was most prevalent in the most recent ones. Overall, total IgE fell significantly (geometric mean ratio: 0.63, 95%CI 0.58 to 0.68), at all ages, in all year-of-birth cohorts.

**Conclusion:** While there was evidence that aging was associated with lower levels of sensitisation to house dust mite and cat, this was not observed for sensitisation to grass.

# Title

Changes in IgE sensitisation and total IgE over 20 years of follow-up

# Authors

André F. S. Amaral<sup>a</sup>, PhD, Roger B. Newson<sup>a,b</sup>, DPhil, Michael Abramson<sup>c</sup>, PhD, Josep M Antó<sup>d,e,f,g</sup>, PhD, Roberto Bono<sup>h</sup>, PhD, Angelo G. Corsico<sup>i</sup>, PhD, Roberto de Marco<sup>j</sup>, PhD, Pascal Demoly<sup>k</sup>, MD, Bertil Forsberg<sup>l</sup>, PhD, Thorarinn Gislason<sup>m,n</sup>, PhD, Joachim Heinrich<sup>o,p</sup>, PhD, Ismael Huerta<sup>q</sup>, MD, Christer Janson<sup>r</sup>, PhD, Rain Jõgi<sup>s</sup>, PhD, Jeong-Lim Kim<sup>t</sup>, PhD, José Maldonado<sup>u</sup>, MD, Jesús Martinez-Moratalla Rovira<sup>v</sup>, MD, Catherine Neukirch<sup>w,x</sup>, MD, Dennis Nowak<sup>y</sup>, MD, Isabelle Pin<sup>z,aa,ab</sup>, MD, Nicole Probst-Hensch<sup>ac,ad</sup>, PhD, Chantal Raherison-Semjen<sup>ae</sup>, PhD, Cecilie Svanes<sup>af,ag</sup>, PhD, Isabel Urrutia Landa<sup>ah</sup>, PhD, Ronald van Ree<sup>ai</sup>, PhD, Serge A. Versteeg<sup>aj</sup>, BSc, Joost Weyler<sup>ak</sup>, PhD, Jan-Paul Zock<sup>d,f,g</sup>, PhD, Peter G. J. Burney<sup>a</sup>, MD, Deborah L. Jarvis<sup>a</sup>, MD

# Affiliations

<sup>a</sup>Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College, London, UK

<sup>b</sup>Department of Primary Care and Public Health, School of Public Health, Imperial College, London, UK

<sup>c</sup>School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia

<sup>d</sup>Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain

<sup>e</sup>IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

<sup>f</sup>Universitat Pompeu Fabra (UPF), Barcelona, Spain

<sup>g</sup>CIBER Epidemiología y Salud Pública (CIBERESP), Spain

<sup>h</sup>Department of Public Health and Pediatrics, University of Turin, Turin, Italy

26 <sup>i</sup>Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation – University of  
27 Pavia, Pavia, Italy

28 <sup>j</sup>Unit of Epidemiology and Medical Statistics, Department of Public Health and Community  
29 Medicine, University of Verona, Verona, Italy

30 <sup>k</sup>Department of Pulmonology - Division of Allergy, Arnaud de Villeneuve Hospital, CHU  
31 Montpellier, France; and EPAR Team - UMR-S 1136 INSERM, Paris, France

32 <sup>l</sup>Division of Occupational and Environmental Medicine, Department of Public Health and  
33 Clinical Medicine, Umeå University, Umeå, Sweden

34 <sup>m</sup>Faculty of Medicine, University of Iceland, Reykjavik, Iceland

35 <sup>n</sup>Department of Respiratory Medicine and Sleep, Landspítali - The National University  
36 Hospital of Iceland, Reykjavik, Iceland

37 <sup>q</sup>Epidemiological Surveillance Section, Directorate General of Public Health, Department of  
38 Health of Asturias, Oviedo, Spain

39 <sup>o</sup>Institute of Epidemiology I, Helmholtz Zentrum, Munich, Germany

40 <sup>p</sup>Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner  
41 City Clinic, University Hospital Munich, Ludwig Maximilian University of Munich, Munich,  
42 Germany

43 <sup>r</sup>Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala  
44 University, Uppsala, Sweden

45 <sup>s</sup>Tartu University Hospital, Lung Clinic, Tartu, Estonia

46 <sup>t</sup>Department of Public Health and Community Medicine, The Sahlgrenska Academy,  
47 University of Gothenburg, Gothenburg, Sweden

48 <sup>u</sup>Unit of Clinical Management of Pneumology and Allergy, University Hospital of Huelva,  
49 Huelva, Spain

50 <sup>v</sup>Unit of Pneumology, University Hospital of Albacete, Albacete, Spain

<sup>w</sup>INSERM UMR1152, Paris, France

<sup>x</sup>Université Paris Diderot Paris 7, UMR1152, Paris, France

<sup>y</sup>Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Inner City Clinic, University Hospital Munich, Ludwig Maximilian University of Munich, Munich, Germany

<sup>z</sup>Pédiatrie, Pole Couple Enfants, CHU de Grenoble, Grenoble, France

<sup>aa</sup>INSERM U823, Institut Albert Bonniot, Grenoble, France

<sup>ab</sup>Université Joseph Fourier, Grenoble, France

<sup>ac</sup>Swiss Tropical and Public Health Institute, Basel, Switzerland

<sup>ad</sup>University of Basel, Basel, Switzerland

<sup>ae</sup>INSERM U897, Institute of Public health and Epidemiology, Bordeaux University, France

<sup>af</sup>Centre for International Health, University of Bergen, Bergen, Norway

<sup>ag</sup>Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway

<sup>ah</sup>Department of Pneumology, Galdakao Hospital, Galdakao, Spain

<sup>ai</sup>Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

<sup>aj</sup>Department of Experimental Immunology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

<sup>ak</sup>Epidemiology and Social Medicine, University of Antwerp, StatUA Statistics Centre, University of Antwerp, Belgium

## **Corresponding author's contact details**

André F. S. Amaral

Respiratory Epidemiology, Occupational Medicine and Public Health

National Heart and Lung Institute, Imperial College London

76 Emmanuel Kaye Building, 1B Manresa Road

77 London SW3 6LR (UK)

78 Tel: +44 (0) 207 594 7940

79 Email: a.amaral@imperial.ac.uk

80

## 81 **Funding**

82 **Australia (Melbourne):** Allen and Hanbury's, National Health and Medical Research

83 Council; **Belgium (Antwerp City and Antwerp South):** Belgian Science Policy Office,

84 National Fund for Scientific Research (G.0402.00), University of Antwerp, Flemish Health

85 Ministry, Research Foundation of Flanders (G.0.410.08.N.10); **Estonia (Tartu):** Estonian

86 Science Foundation (no. 1088, no. 4350), Estonian Ministry of Education (SF0180060s09);

87 **France:** Ministère de la Santé, Glaxo France, Insitut Pneumologique d'Aquitaine, Contrat de

88 Plan Etat-Région Languedoc-Rousillon, CNMATS, CNMRT (90MR/10, 91AF/6), Ministre

89 Delegué de la Santé, RNSP, GSF, Programme Hospitalier de Recherche Clinique National

90 2010, **Bordeaux:** Institut Pneumologique d'Aquitaine, INSERM U897 - Université Bordeaux

91 Segalen, **Grenoble:** Direction de la Recherche Clinique de Grenoble 2000 (no. 2610),

92 Ministère de l'Emploi et de la Solidarité, Direction Générale de la Sante, CHU Grenoble,

93 Comite des Maladies Respiratoires de l'Isere, Comité Scientifique AGIRadom 2011,

94 **Montpellier:** Aventis, Direction Régionale des Affaires Sanitaires et Sociales Languedoc-

95 Roussillon, **Paris:** Ministère de l'Emploi et de la Solidarité, Direction Générale de la Sante,

96 Union Chimique Belge-Pharma, Aventis, Glaxo France, Agence Nationale de la Santé,

97 Région Ile de France, domaine d'intérêt majeur ; **Germany:** Bundesminister für Forschung

98 und Technologie, **Erfurt:** DFG—German Research Foundation (FR1526/1-1, HE 3294/10-

99 1), **Hamburg:** DFG— German Research Foundation (MA 711/4-1, NO 262/7-1); **Iceland**

100 **(Reykjavik):** Icelandic Research Council, Icelandic University Hospital Fund, The

101 Landspítali University Hospital Research Fund, University of Iceland Research Fund,  
 102 ResMed Foundation (California, USA), Orkuveita Reykjavíkur (Geothermal plant),  
 103 Vegagerðin (The Icelandic Road Administration (ICERA)) ; **Italy:** Ministero dell'Università e  
 104 della Ricerca Scientifica e Tecnologica, CNR, Regione Veneto (RSF381/05.93), National  
 105 Board of Health, CHIESI, **Pavia:** GlaxoSmithKline Italy, Local University Funding for  
 106 Research 1998 and 1999, **Turin:** Azienda Sanitaria Locale 4 Regione Piemonte, Azienda  
 107 Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico—  
 108 Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, Department of Public  
 109 Health and Pediatrics. University of Turin, Unit of Respiratory Medicine, National Health  
 110 Service, ASL TO2, **Verona:** Glaxo Wellcome spa, Fondazione Cariverona, Education  
 111 Ministry (MIUR); **Norway (Bergen):** Norwegian Research Council (no. 101422/310, no.  
 112 214123), Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, Norway  
 113 Research Fund, Western Norway Regional Health Authorities (no. 911631), Bergen Medical  
 114 Research Foundation; **Spain:** Ministerio de Sanidad y Consumo FIS (no. 91/0016060/00E-  
 115 05E, no. 93/0393, no. 97/0035-01, no. 99/0034-01, no. 99/0034-02), **Albacete:** Hospital  
 116 General de Albacete, Hospital Universitario de Albacete, Consejería de Sanidad, FIS  
 117 (PS09/02457), **Barcelona:** Sociedad Española de Neumología y Cirugía Torácica, Public  
 118 Health Service (R01 HL62633-01), Consell Interdepartamental de Recerca i Innovacio  
 119 Tecnològica (no. 1999SGR-00241), Instituto de Salud Carlos III, Red de Centros de  
 120 Epidemiología y Salud Pública (C03/09), Red de Bases moleculares y fisiológicas de las  
 121 Enfermedades Respiratorias (C03/011), Red de Grupos Infancia y Medio Ambiente  
 122 (G03/176), FIS (PS09/00716), **Galdakao:** Basque Health Department, FIS (no. 09/01511),  
 123 **Huelva:** Hospital General Juan Ramón Jiménez, FIS (PS09/02185), Servicio Andaluz de  
 124 Salud, **Oviedo:** Consejería de Sanidad Principado de Asturias, FIS (PS09/03190); **Sweden**  
 125 **(Gothenburg, Umea, Uppsala):** Swedish Medical Research Council, Swedish Heart Lung



126 Foundation, Swedish Association against Asthma and Allergy, Swedish Cancer and Allergy  
127 Foundation, Swedish Council for Working Life and Social Research, **Umea**: also received  
128 funding from Vasterbotten Country Council ALF grant; **Switzerland (Basel)**: The Swiss  
129 National Science Foundation (no. 33CS30-148470/1, no. 33CSCO-134276/1, no. 33CSCO-  
130 108796, no. 324730-135673, no. 3247BO-104283, no. 3247BO-104288, no. 3247BO-  
131 104284, no. 3247-065896, no. 3100-059302, no. 3200-052720, no. 3200-042532, no. 4026-  
132 028099, PMPDP3-129021/1, PMPDP3-141671/1), the Federal Office for the Environment,  
133 the Federal Office of Public Health, the Federal Office of Roads and Transport, the canton's  
134 government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zürich,  
135 the Swiss Lung League, the canton's Lung League of Basel Stadt/ Basel Landschaft, Geneva,  
136 Ticino, Valais, Graubünden and Zurich, Stiftung ehemals Bündner Heilstätten, SUVA,  
137 Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics  
138 GmbH, Abbott Diagnostics, European Commission (no. 018996 - GABRIEL), Wellcome  
139 Trust (WT084703MA); **United Kingdom**: Asthma UK (formerly known as National Asthma  
140 Campaign), Department of Health, South Thames Regional Health Authority, Medical  
141 Research Council (G0901214/1). The **co-ordination** of ECRHS I and ECRHS II was  
142 supported by the European Commission. The co-ordination of ECRHS III was supported by  
143 the Medical Research Council (G0901214/1)

## ABSTRACT

**Background:** Cross-sectional studies have reported a lower prevalence of sensitisation in older adults, but few longitudinal studies have examined whether this is an aging or a year-of-birth cohort effect.

**Objective:** To assess changes in sensitisation and total IgE in a cohort of European adults as they aged over 20-year period.

**Methods:** Serum specific IgE to common aeroallergens (house dust mite, cat, grass) and total IgE were measured in 3206 adults, from 25 centres in the European Community Respiratory Health Survey, on three occasions over 20 years. Changes in sensitisation and total IgE were analysed by regression analysis, corrected for potential differences in laboratory equipment, and using inverse sampling-probability weights to account for non-response.

**Results:** Over the 20-year follow-up, the prevalence of sensitisation to at least one of the three allergens fell from 29.4% to 24.8% (-4.6%, 95%CI: -7.0% to -2.1%). The prevalence of sensitisation to house dust mite (-4.3%, 95%CI: -6.0% to -2.6%) and cat (-2.1%, 95%CI: -3.6% to -0.7%) fell more than sensitisation to grass (-0.6%, 95%CI: -2.5% to 1.3%). Age-specific prevalence of sensitisation to house dust mite and cat did not differ between year-of-birth cohorts, but sensitisation to grass was most prevalent in the most recent ones. Overall, total IgE fell significantly (geometric mean ratio: 0.63, 95%CI 0.58 to 0.68), at all ages, in all year-of-birth cohorts.

**Conclusion:** While there was evidence that aging was associated with lower levels of sensitisation to house dust mite and cat, this was not observed for sensitisation to grass.

## **Key messages**

- In a multinational population-based cohort of adults there was a fall in IgE sensitization to house dust mite and cat, but not grass, as the cohort aged over 20 years. Total IgE also fell as the cohort aged.
- The fall in IgE sensitization seemed stronger after 40 years of age.

## **Capsule summary**

After following a large multinational population-based cohort over 20 years, we show that the lower prevalence of IgE sensitisation in older adults is explained by aging.

## **Key words**

Allergens; sensitisation; cohort study; epidemiology; immunoglobulin E; longitudinal analysis; aging; immunosenescence

Population-based cross-sectional studies have shown that the prevalence of sensitisation is higher in younger than in older age groups (1-4). Although there have been year-of-birth cohort-related increases in atopy over the last decades, it is hypothesised that these cross-sectional observations may, in addition, reflect decreases in sensitisation with aging-related immunosenescence. Longitudinal studies that have performed skin prick tests or measured serum allergen specific IgE, at baseline and follow-up over periods of up to 14 years, have reported that sensitisation increased with aging, although changes were less evident in middle-aged and older adults (2, 5-7). Two recent longitudinal studies reported no change or a slight decline in sensitisation with aging (4, 8). In one of these studies, changes in sensitisation were based on allergen specific IgE measures (8), while in the other the comparison between time points was based on both specific IgE and skin prick tests (4). Within the European Community Respiratory Health Survey (ECRHS) (9), a multicentre cohort study of over 6000 young and middle aged adults followed for a 10-year period, there was little evidence of substantial change in sensitisation to at least one of cat, grass or house dust mite (as measured by serum specific IgE) over time as the cohort aged. The age-specific prevalence of sensitisation to grass, but not to the other allergens measured, was higher in more recent year-of-birth cohorts. At the time, it was observed that changes in laboratory methods between the baseline and follow-up could influence assessment of change in sensitisation – such biases are even more difficult to quantify when using skin prick tests. Completion of the third phase of the ECRHS has allowed assessment of serum specific IgE on three occasions: at baseline, ten-year and twenty-year follow-up. The aims of this report were to: 1) to assess the changes in IgE sensitisation and in total IgE in this population-based cohort of European adults over a period of 20 years; and 2) to investigate whether these changes were different between year-of-birth cohorts.

## **METHODS**

### **Study participants**

This is a multicentre population-based cohort study. Detailed descriptions of the methods for ECRHS I and ECRHS II have been published elsewhere (10, 11). In ECRHS I, 1500 men and 1500 women age 20 to 44 years were randomly recruited from community-based sampling frames in each centre. After completing a short postal screening questionnaire, a random sample of responders was selected to complete an interviewer-led questionnaire and provided a blood sample (1991-1993). In the majority of centres, an additional sample of people with symptoms highly suggestive of asthma were recruited for study, but these participants are not included in the present analysis.

In ECRHS II (1998-2002), participants who had completed the extended questionnaire in ECRHS I were re-investigated, and again provided a blood sample. In ECRHS III, those who took part in the clinical stages of ECRHS I and II were again contacted, with responders invited to a local testing centre where, once more, blood samples were taken (2008-2013).

Eleven countries are represented in this report: Iceland (Reykjavik), Norway (Bergen), Sweden (Gothenburg, Umeå, and Uppsala), Estonia (Tartu), Belgium (Antwerp South, and Antwerp City), Germany (Hamburg, and Erfurt), UK (Ipswich, and Norwich), France (Bordeaux, Grenoble, Montpellier, and Paris), Spain (Barcelona, Galdakao, Albacete, Oviedo, and Huelva), Italy (Pavia, Turin, and Verona), and Australia (Melbourne).

Ethical approval for the study from local research ethics committees and written consent from participants were obtained.

### **Measurement of IgE**

In all three surveys, blood samples were obtained and processed under similar conditions.

After clotting and centrifuging, serum was stored at -20 °C until analysis in a single central

laboratory (Pharmacia Uppsala in 1992, Kings College London in 2002, and AMC Amsterdam in 2013/2014) using the Phadia ImmunoCAP system (now Thermo Fisher Scientific, Uppsala, Sweden). To assess the effects of potential laboratory bias on prevalence of IgE sensitisation and mean of total IgE estimates, we conducted duplicate assays on 794 samples (tested at ECRHS I, stored, and tested at ECRHS II) and 475 samples (tested at ECRHS II, stored, and tested at ECRHS III) (online table 1). The methods for this correction are described in detail in the online supplement.

## Outcomes

Participants were considered to be sensitised if allergen specific IgE to *Dermatophagoides pteronyssinus* (house dust mite), *Felis silvestris catus* (cat), and *Phleum pratense* (Timothy grass) was present in concentrations  $>0.35$  kU<sub>A</sub>/L. A higher threshold ( $>0.70$  kU<sub>A</sub>/L) was also considered. ‘Atopy’ was defined as being sensitised to one of either house dust mite, grass or cat. Total IgE, expressed in kilounits/litre (kU/L), was log-transformed and considered as a continuous outcome for estimation of geometric means and their ratios.

## Statistical methods

Statistical analyses were performed using Stata V.13 (StataCorp LP, College Station, TX). Analyses were restricted to the 3206 participants with information on serum specific IgE and total IgE in all three ECRHS surveys (Figure 1). Inverse sampling-probability weights were used to standardise the estimation from this population with data on IgE assays from all three ECRHS surveys to the original target population of participants with data on IgE assays from ECRHS I (see online supplement for details on the inverse sampling-probability weighted estimation).

The prevalence of sensitisation at each survey was determined using logistic regression with Huber variances considering participants as the clusters. Confidence intervals for prevalences, and their differences (net change) between ECRHS II and I, ECRHS III and II, and ECRHS III and I were estimated using the normalising hyperbolic-arctangent transformation (12). Similarly, using linear regression, we calculated geometric mean (GM) ratios of total IgE between ECRHS II and I, ECRHS III and II, and ECRHS III and I. We used the `margins` and `nlcom` commands in Stata to do this and the `regpar` add-on package (13) as required.

Statistical analyses for each outcome were performed in two ways, using uncorrected models and models corrected for potential laboratory bias. Only results of the corrected models are presented in this report. As data came from multiple centres, we tested for between-centre heterogeneity in the uncorrected results using the methods of Cochran (14).

In a final step, analyses were repeated: 1) stratified by gender; 2) restricted to lifetime non-smokers; and c) by year-of-birth cohort. For this latter step, year-of-birth cohorts were defined by date of birth (1964-1973, 1954-1963, 1944-1953). The ages of these participants at 1 January 1992 (the approximate midpoint of ECRHS I data collection) would have been  $18 \leq \text{age} < 28$ ,  $28 \leq \text{age} < 38$  and  $38 \leq \text{age} \leq 48$  years, respectively (participants from Tartu, Estonia, were recruited aged 20-44 in 1994 and would have been less than 20 years on 1 January 1992, hence 18 years is the lower age limit). Members of each age cohort would have been 10 years older on 1 January 2002 (during the ECRHS II data collection) and 20 years older on 1 January 2012 (during the ECRHS III data collection). This approach allowed comparison of earlier cohorts with later cohorts at approximately the same ages.

## RESULTS

A total of 3206 (30.6%) of the 10,478 participants who provided a blood sample in the first survey took part and again provided a sample in both ECRHS II and III. The median age of participants at ECRHS I was 34.9 years (interquartile range: 28.6-40.5), half were males, and forty five percent were lifetime non-smokers. There was variation between centres in the proportion of participants who provided samples at ECRHS I and then went on to provide samples at ECRHS II and ECRHS III (minimum: 13.6% in Pavia; maximum: 58.6% in Reykjavik). Factors associated with response were older age, and being a non-smoker. Response was not associated with sensitisation at baseline, gender, and reporting of wheeze (online table 2), although those who took part in all three surveys did report waking with breathlessness less frequently.

### Net change in IgE sensitisation and total IgE

Laboratory-corrected net changes in prevalence of IgE sensitisation to each of the allergens and in geometric mean of total IgE over a period of 20 years are shown in table 1. Between ECRHS I and ECRHS II there was no significant change in the prevalence of IgE sensitisation to any of the allergens using either the low or the high cut-off levels. Over the 20 years of follow up, i.e. between ECRHS I and ECRHS III, prevalence of IgE sensitisation to house dust mite, cat, and to at least one allergen fell. Using the 0.35 kU<sub>A</sub>/L cut-off, the prevalence of sensitisation to grass remained stable, but when the 0.70 kU<sub>A</sub>/L cut-off was used there was evidence of a reduction in sensitisation. These changes were similar in men and women (online table 3). For some estimates there was evidence of heterogeneity between countries, but no clear pattern by latitude (figure 2) or response rate (online figure 1) in this variation was observed.



Overall there was a significant fall in total IgE over the 20 years of follow up (geometric mean ratio: 0.63, 95% CI 0.58 to 0.68). This generalised fall in total IgE occurred in all centres, although the magnitude of the change varied (heterogeneity between centres  $P < 0.001$ ; online figure 2). Patterns were similar in men and women (online table 3). Restriction of analyses to the 1304 participants who were lifetime non-smokers did not materially alter the results reported above (online table 4).

### **Association of net change with age and cohort**

In ECRHS I, the prevalence of IgE sensitisation to house dust mite, grass, cat, and to at least one allergen was higher in younger adults (i.e. those born more recently) than in older adults (table 2).

Over the 20-year period, the prevalence of sensitisation to house dust mite fell in all age groups to a similar extent, and there was little evidence that the age-specific prevalence of sensitisation to house dust mite was different between those born more recently and those born earlier (figure 3A). Overall the picture was one of a decrease in sensitisation with age, with decreases occurring throughout adult life. This was broadly similar for sensitisation to cat (figure 3C). However, these patterns were different for sensitisation to grass. Although there was evidence of a fall in sensitisation to grass in those who were the oldest at recruitment (i.e. the earlier cohort), falls were not seen in those who were born more recently. As a result, there were marked differences in the age-specific prevalence of sensitisation to grass between cohorts with higher age-specific prevalence in those born after 1964 (figure 3B). The prevalence of IgE sensitisation to at least one of house dust mite, grass and cat showed a pattern similar to that of sensitisation to house dust mite and cat. The most recent cohort had the highest prevalence at younger ages, but these cohort-related differences were

325 not apparent in later adult life (figure 3D). Similar patterns were observed when using the  
326 cut-off of 0.70 kU<sub>A</sub>/L (online table 5).

327 The population GM of total IgE was lower at each follow up, in all cohorts over the 20-year  
328 period of follow up, and the more recent cohorts had lower levels of total IgE than those born  
329 earlier at the equivalent ages (figure 4, table 2).

330

## DISCUSSION

We have shown that the prevalence of sensitisation to at least one of house dust mite, cat or grass has decreased within a large population-based adult cohort followed over a period of 20 years. There was a decrease in the prevalence of sensitisation to house dust mite, and to cat, and the geometric mean total IgE levels also decreased. Sensitisation to grass did not follow these patterns so clearly, showing, instead, an increase in younger ages and aging effects only at older ages.

Strengths of this study are the population-based nature of the sample derived from several parts of Europe and Australia, the prolonged period of follow-up and the standardised handling and testing of samples between centres and over time. Changes in laboratory staff, consumables and methods between surveys could lead to bias in prevalence estimates and to address this we have used information from duplicate assays of hundreds of samples to adjust our estimates. As with all cohorts, there has been attrition during the 20-year period of follow-up and the analyses we present are based on participants who have taken part in all three phases of the study. We are aware that considerable loss to follow up has the potential to induce bias, therefore to account for small differences between these individuals and the initial cohort at baseline and to enhance the external validity of our results, we have corrected our models with inverse sampling-probability weights. This method generates estimates that apply to the population we sampled at baseline.

To date, few other population-based studies have reported on longitudinal changes in sensitisation by measuring serum specific IgE levels (6, 8). These earlier reports, both in Denmark, are on smaller samples and mostly over shorter time periods. Linneberg et al. studied changes over an 8-year period in serum specific IgE to at least one of six allergens in about 400 adolescents and adults in Copenhagen (6), reporting an increase in prevalence of IgE sensitisation, especially among those born in the 1960s or later. Older adults (above 40

356 years, n = 695) living in the same city and followed for 20 years showed no change in  
357 sensitisation over a 20-year period in prevalence of IgE sensitisation to at least one of 19  
358 allergens (8). Other studies looked at changes in sensitisation by performing skin prick tests  
359 and reported increases with aging (2, 4, 5). However, skin prick tests are much more difficult  
360 to standardise over different periods as they are prone to fieldworker variation, with changes  
361 in skin prick test reagents being difficult to assess (15, 16).

362 Barbee et al. studied 1100 participants in the US and reported a decrease in levels of total IgE  
363 with age in children and young adults, but not in older adults (17). In the ECRHS, total IgE  
364 levels fell with aging within each cohort, with more recent cohorts having lower levels of  
365 total IgE than earlier ones at the same age. In a previous report, we showed that smoking  
366 associated differently with sensitisation to different aeroallergens, and in a dose-response  
367 manner with total IgE levels (18). Therefore, we hypothesized that changes in sensitisation  
368 over time could be related to declining smoking rates and that lifetime non-smokers would  
369 not show changes in sensitisation. Our present findings show that a decline in sensitisation is  
370 unlikely to be related to smoking cessation. The fall in total IgE in our study may in part be  
371 explained by a decline in helminthic infestation as observed by others in children (19).

372 We saw no evidence of change in the prevalence of IgE sensitisation to house dust mite, cat,  
373 grass, and at least one of these three as the cohort aged over the initial 10 years of follow-up  
374 of the ECRHS (9). This observation is confirmed within this second report, but we go on to  
375 show that prevalence does decrease over 20 years, and appears greater when people are aged  
376 about 40 or older. This finding may be explained by immunosenescence, which seems to be  
377 more evident after 50 years of age (20) and corresponds to age-related changes in the number  
378 and function of cells from the immune system (21). The production of IgE, which is  
379 dependent on an interaction between B cells and T cells (22), may decline as a consequence

of the naturally occurring involution of the thymus (23) – the thymic output of T cells per day in a 50-year old is about 33% lower than that of a 25-year old (23).

Our findings are supported by animal studies, which suggest that the production of IgE to an allergen challenge is higher in younger than older animals (24, 25). In one of these studies, the transplant of thymocytes into young (8 weeks old) mice resulted in no change in IgE response, whereas that into aged (65 weeks old) mice resulted in an enhanced IgE response similar to that of young mice (25).

One might expect all markers of atopy to follow similar age/period/cohort patterns. Our report suggests grass may be different to house dust mites and cat, but we can only speculate as to the reason for this. There are differences in the epidemiology of each, particularly with respect to factors associated with the 'hygiene hypothesis'. Larger sibships protect younger siblings from hay fever and from sensitisation to grass more strongly than from asthma and sensitisation to house dust mites (26, 27). Declining family size over the last decades may explain the less marked aging effect for grass than for other allergens. Changes in the level of exposure to pollens may have had a role in our findings (28, 29). There are also reports suggesting that pollens in our more modern society are more allergenic than they have been previously (30, 31), which could be related to the high levels of air pollutants such as ozone, nitrogen dioxide and carbon dioxide (31-33). The presence of unmeasured factors may also have a role in the different patterns observed in the sensitisation to the three allergens.

In summary, over a period of 20 years the prevalence of specific IgE sensitisation to house dust mite and cat, but not grass, significantly fell in the multinational cohort of adults from the ECRHS as a consequence of aging, being more evident among those aged 40 or over.

## ACKNOWLEDGEMENTS

We would like to thank the participants, field workers, and data managers of this study for their time and cooperation.

## REFERENCES

1. Salo PM, Arbes SJ, Jr., Jaramillo R, Calatroni A, Weir CH, Sever ML, et al. Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006. *J Allergy Clin Immunol.* 2014;134:350-9.
2. Broadfield E, McKeever TM, Scrivener S, Venn A, Lewis SA, Britton J. Increase in the prevalence of allergen skin sensitization in successive birth cohorts. *J Allergy Clin Immunol.* 2002;109:969-74.
3. Linneberg A, Gislum M, Johansen N, Husemoen LL, Jorgensen T. Temporal trends of aeroallergen sensitization over twenty-five years. *Clin Exp Allergy.* 2007;37:1137-42.
4. Warm K, Backman H, Lindberg A, Lundback B, Ronmark E. Low incidence and high remission of allergic sensitization among adults. *J Allergy Clin Immunol.* 2012;129:136-42.
5. Barbee RA, Kaltenborn W, Lebowitz MD, Burrows B. Longitudinal changes in allergen skin test reactivity in a community population sample. *J Allergy Clin Immunol.* 1987;79:16-24.
6. Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T. Is the increase in allergic respiratory disease caused by a cohort effect? *Clin Exp Allergy.* 2002;32:1702-5.
7. Dottorini ML, Bruni B, Peccini F, Bottini P, Pini L, Donato F, et al. Skin prick-test reactivity to aeroallergens and allergic symptoms in an urban population of central Italy: a longitudinal study. *Clin Exp Allergy.* 2007;37:188-96.

- 430 8. Linneberg A, Friedrich N, Husemoen LL, Thuesen B, Gonzalez-Quintela A, Vidal C,  
431 et al. Incidence and remission of specific IgE aeroallergen sensitization from age of 40 to 60  
432 years, and association with alcohol consumption. *Int Arch Allergy Immunol.* 2010;151:142-8.
- 433 9. Jarvis D, Luczynska C, Chinn S, Potts J, Sunyer J, Janson C, et al. Change in  
434 prevalence of IgE sensitization and mean total IgE with age and cohort. *J Allergy Clin*  
435 *Immunol.* 2005;116:675-82.
- 436 10. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory  
437 Health Survey. *Eur Respir J.* 1994;7:954-60.
- 438 11. European Community Respiratory Health Survey II SC. The European Community  
439 Respiratory Health Survey II. *Eur Respir J.* 2002;20:1071-9.
- 440 12. Fisher RA. On the 'probable error' of a coefficient of correlation deduced from a small  
441 sample. *Metron.* 1921;1:1-32.
- 442 13. Newson RB. Attributable and unattributable risks and fractions and other scenario  
443 comparisons. *The Stata Journal* 2013;13:672–98.
- 444 14. Cochran WG. The combination of estimates from different experiments. *Biometrics.*  
445 1954;10:101-29.
- 446 15. Bousquet J, Heinzerling L, Bachert C, Papadopoulos NG, Bousquet PJ, Burney PG, et  
447 al. Practical guide to skin prick tests in allergy to aeroallergens. *Allergy.* 2012;67:18-24.
- 448 16. Werther RL, Choo S, Lee KJ, Poole D, Allen KJ, Tang ML. Variability in skin prick  
449 test results performed by multiple operators depends on the device used. *World Allergy*  
450 *Organ J.* 2012;5:200-4.
- 451 17. Barbee RA, Halonen M, Kaltenborn W, Lebowitz M, Burrows B. A longitudinal  
452 study of serum IgE in a community cohort: correlations with age, sex, smoking, and atopic  
453 status. *J Allergy Clin Immunol.* 1987;79:919-27.

- 454 18. Jarvis D, Chinn S, Luczynska C, Burney P. The association of smoking with  
455 sensitization to common environmental allergens: results from the European Community  
456 Respiratory Health Survey. *J Allergy Clin Immunol.* 1999;104:934-40.
- 457 19. Flohrs K, Bruske I, Thiering E, Rzehak P, Wichmann HE, Heinrich J. Temporal  
458 changes in total serum immunoglobulin E levels in East German children and the effect of  
459 potential predictors. *Int Arch Allergy Immunol.* 2012;158:27-34.
- 460 20. Rubelt F, Sievert V, Knaust F, Diener C, Lim TS, Skriner K, et al. Onset of immune  
461 senescence defined by unbiased pyrosequencing of human immunoglobulin mRNA  
462 repertoires. *PLoS One.* 2012;7:e49774.
- 463 21. Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, Zanlari L, et al. The immune  
464 system in extreme longevity. *Exp Gerontol.* 2008;43:61-5.
- 465 22. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch  
466 recombination. *Nat Rev Immunol.* 2003;3:721-32.
- 467 23. Haynes BF, Sempowski GD, Wells AF, Hale LP. The human thymus during aging.  
468 *Immunol Res.* 2000;22:253-61.
- 469 24. Yagi T, Sato A, Hayakawa H, Ide K. Failure of aged rats to accumulate eosinophils in  
470 allergic inflammation of the airway. *J Allergy Clin Immunol.* 1997;99:38-47.
- 471 25. Fujiwara M, Kishimoto S. IgE antibody formation and aging. I. Age-related changes  
472 in IgE antibody formation and avidity for the DNP-determinant in mice. *J Immunol.*  
473 1979;123:263-8.
- 474 26. Strachan DP. Hay fever, hygiene, and household size. *BMJ.* 1989;299:1259-60.
- 475 27. Svanes C, Jarvis D, Chinn S, Burney P. Childhood environment and adult atopy:  
476 results from the European Community Respiratory Health Survey. *J Allergy Clin Immunol.*  
477 1999;103:415-20.



- 478 28. Ziello C, Sparks TH, Estrella N, Belmonte J, Bergmann KC, Bucher E, et al. Changes  
479 to airborne pollen counts across Europe. *PLoS One*. 2012;7:e34076.
- 480 29. Smith M, Jager S, Berger U, Sikoparija B, Hallsdottir M, Sauliene I, et al. Geographic  
481 and temporal variations in pollen exposure across Europe. *Allergy*. 2014;69:913-23.
- 482 30. D'Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, et al.  
483 Allergenic pollen and pollen allergy in Europe. *Allergy*. 2007;62:976-90.
- 484 31. Ackaert C, Kofler S, Horejs-Hoeck J, Zulehner N, Asam C, von Grafenstein S, et al.  
485 The impact of nitration on the structure and immunogenicity of the major birch pollen  
486 allergen Bet v 1.0101. *PLoS One*. 2014;9:e104520.
- 487 32. Albertine JM, Manning WJ, DaCosta M, Stinson KA, Muilenberg ML, Rogers CA.  
488 Projected carbon dioxide to increase grass pollen and allergen exposure despite higher ozone  
489 levels. *PLoS One*. 2014;9:e111712.
- 490 33. Olivier JGJ, Janssens-Maenhout G, Muntean M, Peters JAHW. Trends in global CO<sub>2</sub>  
491 emissions: 2013 Report. The Hague: PBL Netherlands Environmental Assessment Agency,  
492 2013.

493

Table 1. Net change in IgE sensitisation to house dust mite, grass, and cat, and total IgE over 20 years (N = 3206).

	Prevalence (%) ECRHS I	Net change (95% CI) ECRHS II vs I	<i>P</i> for heterogeneity between centres	Net change (95% CI) ECRHS III vs I	<i>P</i> for heterogeneity between centres
<b>House dust mite</b>					
(>0.35 kU <sub>A</sub> /L)	16.6	-0.7 (-2.2 to 0.9)	0.051	-4.3 (-6.0 to -2.6)	0.71
(>0.70 kU <sub>A</sub> /L)	13.1	-0.7 (-1.9 to 0.4)	0.63	-3.1 (-4.5 to -1.7)	0.21
<b>Grass</b>					
(>0.35 kU <sub>A</sub> /L)	17.0	0.5 (-1.0 to 2.0)	0.048	-0.6 (-2.5 to 1.3)	0.009
(>0.70 kU <sub>A</sub> /L)	14.2	0.0 (-1.3 to 1.3)	0.48	-2.2 (-3.8 to -0.6)	0.97
<b>Cat</b>					
(>0.35 kU <sub>A</sub> /L)	8.8	-0.9 (-2.1 to 0.3)	0.14	-2.1 (-3.6 to -0.7)	0.09
(>0.70 kU <sub>A</sub> /L)	6.4	0.0 (-1.0 to 1.1)	0.15	-1.1 (-2.2 to 0.1)	0.04
<b>House dust mite or grass or cat</b>					
(>0.35 kU <sub>A</sub> /L)	29.4	0.1 (-2.0 to 2.1)	0.003	-4.6 (-7.0 to -2.1)	0.03
(>0.70 kU <sub>A</sub> /L)	24.2	-0.6 (-2.2 to 1.0)	0.11	-4.6 (-6.6 to -2.6)	0.17
	GM ECRHS I	GM ratio (95% CI) ECRHS II vs I	<i>P</i> for heterogeneity between centres	GM ratio (95% CI) ECRHS III vs I	<i>P</i> for heterogeneity between centres
<b>Total IgE</b> (kU/L)	29.8	0.84 (0.78 to 0.90)	< 0.001	0.63 (0.58 to 0.68)	< 0.001

GM, Geometric mean.

Table 2. Net change in IgE sensitisation (>0.35 kU<sub>A</sub>/L) to house dust mite, grass, and cat, and total IgE (kU/L) over 20 years, by year-of-birth cohort.

	1964-1973 (N = 736)			1954-1963 (N = 1314)			1944-1953 (N = 1156)		
	Prevalence or GM	Net change (95% CI)		Prevalence or GM	Net change (95% CI)		Prevalence or GM	Net change (95% CI)	
	ECRHS I	ECRHS II vs I	ECRHS III vs I	ECRHS I	ECRHS II vs I	ECRHS III vs I	ECRHS I	ECRHS II vs I	ECRHS III vs I
<b>House dust mite</b>	18.6	-0.6 (-3.0 to 1.8)	-4.1 (-6.7 to -1.5)	17.2	0.2 (-1.9 to 2.4)	-4.5 (-6.9 to -2.1)	13.8	-2.0 (-3.9 to -0.1)	-4.3 (-6.6 to -1.9)
<b>Grass</b>	20.6	3.3 (0.4 to 6.2)	1.5 (-1.8 to 4.9)	15.9	0.5 (-1.4 to 2.3)	-0.1 (-2.5 to 2.3)	15.4	-1.9 (-3.8 to 0.0)	-3.2 (-5.3 to -1.0)
<b>Cat</b>	10.5	0.2 (-2.2 to 2.6)	-0.7 (-3.5 to 2.0)	8.3	-1.4 (-2.9 to 0.1)	-2.0 (-3.6 to -0.3)	8.1	-1.2 (-2.7 to 0.2)	-3.6 (-5.2 to -2.0)
<b>House dust mite or grass or cat</b>	33.5	1.9 (-1.3 to 5.1)	-2.1 (-6.1 to 1.9)	28.7	1.1 (-1.6 to 3.7)	-4.1 (-7.2 to -1.1)	26.5	-3.0 (-5.6 to -0.3)	-7.4 (-10.4 to -4.3)
<b>Total IgE</b>	29.9	0.81 (0.72 to 0.91)	0.61 (0.54 to 0.68)	31.3	0.85 (0.78 to 0.92)	0.61 (0.56 to 0.67)	27.9	0.84 (0.78 to 0.92)	0.68 (0.61 to 0.75)

GM, Geometric mean.


## Figures legends

**Figure 1.** Participant flow in the European Community Respiratory Health Survey (only centres that took part in all three surveys are included).

**Figure 2.** Net change in prevalence of IgE sensitisation (cut-off: 0.35 kU<sub>A</sub>/L) to house dust mite [ $I^2$  (heterogeneity) = 0.0%,  $P$  = 0.71)], grass ( $I^2$  = 44.9%,  $P$  = 0.009), cat ( $I^2$  = 29.0%,  $P$  = 0.09), and at least one of these allergens ( $I^2$  = 38.6%,  $P$  = 0.03). Centres are sorted by latitude (from North to South).



**Figure 3.** Prevalence of IgE sensitisation to (A) house dust mite, (B) grass, (C) cat, and (D) at least one of these three allergens, over 20 years of follow up, by year-of-birth cohort.

**Figure 4.** Changes in total IgE (kU/L) over 20 years of follow up, by year-of-birth cohort.







**Figure 1.** Participant flow in the European Community Respiratory Health Survey (only centres that took part in all three surveys are included).

Figure No. 2  
Click here to download Figure No.: fig2\_panel.pdf



**Figure No. 3**  
[Click here to download Figure No.: fig3\\_before\\_fig3-6.pdf](#)




Birth cohort

.....○..... 1964-1973    - -◇- - 1954-1963    - -□- - 1944-1953

Birth cohort

.....○..... 1964-1973    - -◇- - 1954-1963    - -□- - 1944-1953

Figure No. 4  
[Click here to download Figure No.: fig4\\_before\\_fig7\\_gmreg5\\_2\\_2.pdf](#)





## Online methods

Statistical analyses were performed using Stata V.13 (StataCorp LP, College Station, TX).

### Laboratory bias (duplicate measurements)

To assess the effects of potential laboratory bias on prevalence of IgE sensitisation and mean of total IgE estimates, we conducted duplicate assays on 794 samples (tested at ECRHS I, stored, and tested at ECRHS II) and 475 samples (tested at ECRHS II, stored, and tested at ECRHS III). Confidence intervals for Cohen's kappa statistics for each comparison between two measurements of the same sample were computed using the kap command in Stata, together with delta-method standard errors, using the normalising and variance-stabilising transformation  $\ln(1-\text{kappa})$  (online table 1).

### Elimination of laboratory bias

To correct our estimates for laboratory bias, we included in the models:

- the three main-assessment assays for each participant (GMs or odds for each combination of centre and ECRHS survey);
- four extra parameters (GM ratios or odds ratios) regarding the paired method-comparison assays:
  - two indicating an assay's membership in the two method-comparison studies;
  - two indicating that an assay was carried out using the method of ECRHS II or III, respectively, instead of the method of ECRHS I.

## Inverse sampling-probability weighted estimation

Inverse sampling-probability weights were used to standardise the estimation from the population with data on IgE assays in all three ECRHS surveys to a target population of participants with data on IgE assays from ECRHS I, which was randomly sampled from the general adult population in different European and Australian centres.

The inverse sampling-probability weights were calculated using a logistic regression model (1) with a separate set of parameters for each centre with any IgE data responders, predicting response to all three surveys from baseline characteristics, adapted from the response-regression model of Jarvis et al. (2). The parameters for each centre were a baseline odds, an exponential per-decade odds ratio for age at 01 January 1992, an odds ratio for female gender (compared to a baseline of male gender), odds ratios for self-reported smoking status at ECRHS I ('ex' and 'current' compared to a baseline of 'never'), an odds ratio for wheeze at ECRHS I, an odds ratio for waking with shortness of breath at ECRHS I, and an odds ratio for IgE sensitisation to house dust mite, cat, or grass at ECRHS I. When we meta-analysed the parameters using randomly-variable-effects meta-analysis (3), we found that participants who have taken part in all three phases of the study were slightly older, less likely to be smokers and less likely to have reported shortness of breath than participants who did not have serum IgE in all three surveys (online table 2).

The use of inverse sampling-probability weights to standardise the estimates to the target population in ECRHS I seemed to work, as indicated by a Somers' D of response-propensity score (4) with respect to response of 0.008 when inverse sampling-probability weighted versus one of 0.239 when unweighted.

## References

1. Robins JM, et al. Estimation of regression coefficients when some regressors are not always observed. *Journal of the American Statistical Association*. 1994;89:846-66.
2. Jarvis D, et al. Change in prevalence of IgE sensitization and mean total IgE with age and cohort. *J Allergy Clin Immunol*. 2005;116:675-82.
3. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-88.
4. Newson R. Confidence intervals for rank statistics: Somers' D and extensions. *Stata Journal*. 2006;6:309.

	IgE in 1992		IgE in 2002		% difference 2002 vs 1992 (95% CI)	Cohen kappa 2002 vs 1992	IgE in 2002		IgE in 2013/14		% between 2013/14 vs 2002 (95% CI)	Cohen kappa 2013/14 vs 2002
	N (of 794)	%	N (of 794)	%	N = 794		N (of 475)	%	N (of 475)	%	N = 475	
House dust mite (0.35 kU <sub>A</sub> /L)	241	30.4	247	31.1	0.8 (-1.3 to 2.8)	0.80	129	27.2	133	28.0	0.8 (-0.6 to 2.3)	0.94
(0.70 kU <sub>A</sub> /L)	193	24.3	195	24.6	0.3 (-1.1 to 1.6)	0.89	106	22.3	104	21.9	-0.4 (-1.4 to 0.6)	0.96
Grass (0.35 kU <sub>A</sub> /L)	229	28.8	224	28.2	-0.6 (-2.3 to 1.1)	0.86	119	25.1	115	24.2	-0.8 (-2.1 to 0.5)	0.94
(0.70 kU <sub>A</sub> /L)	187	23.6	196	24.7	1.1 (-0.3 to 2.6)	0.88	99	20.8	98	20.6	-0.2 (-1.6 to 1.2)	0.93
Cat (0.35 kU <sub>A</sub> /L)	116	14.6	133	16.8	2.1 (0.7 to 3.6)	0.83	60	12.6	63	13.3	0.6 (-0.7 to 2.0)	0.90
(0.70 kU <sub>A</sub> /L)	94	11.8	102	12.8	1.0 (-0.3 to 2.3)	0.85	51	10.7	54	11.4	0.6 (-0.5 to 1.7)	0.92
Sensitisation to at least one allergen (0.35 kU <sub>A</sub> /L)	336	42.3	338	42.6	0.3 (-1.8 to 2.3)	0.82	182	38.3	186	39.2	0.8 (-0.9 to 2.6)	0.92
(0.70 kU <sub>A</sub> /L)	278	35.0	293	36.9	1.9 (0.4 to 3.4)	0.89	159	33.5	162	34.1	0.6 (-0.7 to 2.0)	0.95
	GM in 1992 N = 794		GM in 2002 N = 794		GM ratio 2002 vs 1992 (95% CI)		GM in 2002 N = 475		GM in 2013/14 N = 475		GM ratio 2013/14 vs 2002 (95% CI)	
Total IgE (kU/L)	36.1		52.75		1.46 (1.38-1.55)		42.7		43.2		1.01 (0.98-1.05)	

GM, Geometric mean.

Online table 2. Baseline characteristics of subjects with IgE measurements in all three surveys of ECRHS versus subjects with IgE measurements in baseline survey only from same centres.

	With IgE measurements in baseline survey only (n = 7272)	With IgE measurements in all three surveys (n = 3206)	Adjusted* odds for responding (95% CI)	P for heterogeneity#
Age at baseline (per 10 years)	-	-	1.40 (1.29-1.52)	0.036
Female (%)	49.9	50.0	1.00 (0.19-1.11)	0.17
Smoking status at baseline (%)				
Lifetime non-smoker	41.6	45.1	1.00	
Ex-smoker	21.1	22.6	0.88 (0.78-1.01)	0.29
Current smoker	37.3	32.3	0.65 (0.58-0.73)	0.38
Symptoms in the last 12 months				
Wheeze	22.2	19.8	0.97 (0.84-1.11)	0.12
Woken with shortness of breath	6.4	4.8	0.76 (0.61-0.94)	0.40
Sensitised to at least one allergen** (%)	29.5	27.9	1.05 (0.91-1.22)	0.0017

\*From meta-analysis by centre, adjusting for all other factors in table.

\*\*House dust mite, cat, grass.

#From random effects meta-analysis.

Online table 3. Net change in IgE sensitisation to house dust mite, grass, and cat, and total IgE over 20 years, by gender.

	Males (n = 1604)					Females (n = 1602)				
	Prevalence (%) ECRHS I	Net change (95% CI) ECRHS II vs I	P for heterogeneity between centres	Net change (95% CI) ECRHS III vs I	P for heterogeneity between centres	Prevalence (%) ECRHS I	Net change (95% CI) ECRHS II vs I	P for heterogeneity between centres	Net change (95% CI) ECRHS III vs I	P for heterogeneity between centres
<b>House dust mite</b>										
(>0.35 kU <sub>A</sub> /L)	19.7	-0.5 (-2.7 to 1.6)	0.20	-5.0 (-7.2 to -2.8)	0.59	13.5	-0.8 (-2.5 to 0.9)	0.038	-3.7 (-5.7 to -1.7)	0.34
(>0.70 kU <sub>A</sub> /L)	15.1	-0.3 (-2.0 to 1.4)	0.95	-2.9 (-4.9 to -0.9)	0.26	11.0	-1.1 (-2.3 to 0.1)	0.096	-3.3 (-5.0 to -1.6)	0.057
<b>Grass</b>										
(>0.35 kU <sub>A</sub> /L)	18.5	0.4 (-1.6 to 2.4)	0.18	-0.9 (-3.2 to 1.3)	0.11	15.6	0.6 (-1.2 to 2.4)	0.94	-0.2 (-2.5 to 2.1)	0.74
(>0.70 kU <sub>A</sub> /L)	15.8	-0.3 (-2.0 to 1.5)	0.16	-3.1 (-5.1 to -1.0)	0.82	12.7	0.3 (-1.2 to 1.8)	0.91	-1.3 (-3.3 to 0.6)	0.95
<b>Cat</b>										
(>0.35 kU <sub>A</sub> /L)	8.7	-0.3 (-1.9 to 1.3)	0.21	-2.1 (-3.8 to -0.4)	0.40	8.9	-1.5 (-2.9 to -0.1)	0.54	-2.2 (-3.9 to -0.5)	0.074
(>0.70 kU <sub>A</sub> /L)	6.4	0.2 (-1.2 to 1.6)	0.22	-1.2 (-2.7 to 0.3)	0.27	6.4	-0.1 (-1.4 to 1.1)	0.071	-1.0 (-2.3 to 0.4)	0.013
<b>House dust mite or grass or cat</b>										
(>0.35 kU <sub>A</sub> /L)	32.5	0.8 (-1.8 to 3.5)	0.74	-5.6 (-8.6 to -2.5)	0.39	26.2	-0.7 (-3.0 to 1.6)	0.46	-3.6 (-6.4 to -0.7)	0.089
(>0.70 kU <sub>A</sub> /L)	26.5	0.3 (-2.0 to 2.5)	0.81	-4.6 (-7.2 to -2.0)	0.25	21.9	-1.5 (-3.2 to 0.3)	0.40	-4.5 (-6.8 to -2.2)	0.056
	<b>GM ECRHS I</b>	<b>GM ratio (95% CI) ECRHS II vs I</b>	<b>P for heterogeneity between centres</b>	<b>GM ratio (95% CI) ECRHS III vs I</b>	<b>P for heterogeneity between centres</b>	<b>GM ECRHS I</b>	<b>GM ratio (95% CI) ECRHS II vs I</b>	<b>P for heterogeneity between centres</b>	<b>GM ratio (95% CI) ECRHS III vs I</b>	<b>P for heterogeneity between centres</b>
<b>Total IgE (kU/L)</b>	34.3	0.82 (0.75 to 0.88)	< 0.001	0.65 (0.59 to 0.71)	< 0.001	26.0	0.86 (0.79 to 0.93)	0.004	0.61 (0.56 to 0.67)	< 0.001

GM, Geometric mean.

Online table 4. Net change in IgE sensitisation to house dust mite, grass, and cat, and total IgE over 20 years: Persistent lifetime non-smokers only (N = 1304).



	Prevalence (%) ECRHS I	Net change (95% CI) ECRHS II vs I	<i>P</i> for heterogeneity between centres	Net change (95% CI) ECRHS III vs I	<i>P</i> for heterogeneity between centres
<b>House dust mite</b>					
(>0.35 kU <sub>A</sub> /L)	15.8	0.0 (-1.9 to 2.0)	0.005	-3.4 (-5.5 to -1.4)	0.08
(>0.70 kU <sub>A</sub> /L)	12.4	-0.9 (-2.2 to 0.5)	0.79	-2.0 (-3.8 to -0.2)	0.41
<b>Grass</b>					
(>0.35 kU <sub>A</sub> /L)	20.5	1.1 (-1.0 to 3.3)	0.75	-0.4 (-3.0 to 2.2)	0.26
(>0.70 kU <sub>A</sub> /L)	17.9	0.2 (-1.6 to 2.1)	0.65	-2.5 (-4.9 to -0.1)	0.98
<b>Cat</b>					
(>0.35 kU <sub>A</sub> /L)	10.5	-0.6 (-2.3 to 1.1)	0.78	-2.0 (-4.1 to 0.0)	0.42
(>0.70 kU <sub>A</sub> /L)	8.0	0.4 (-1.2 to 2.0)	0.71	-0.8 (-2.5 to 1.0)	0.42
<b>House dust mite or grass or cat</b>					
(>0.35 kU <sub>A</sub> /L)	31.4	1.9 (-0.8 to 4.5)	0.002	-2.9 (-6.0 to 0.2)	0.03
(>0.70 kU <sub>A</sub> /L)	26.7	0.1 (-1.9 to 2.2)	0.21	-3.3 (-5.9 to -0.6)	0.21
	GM ECRHS I	GM ratio (95% CI) ECRHS II vs I	<i>P</i> for heterogeneity between centres	GM ratio (95% CI) ECRHS III vs I	<i>P</i> for heterogeneity between centres
<b>Total IgE</b> (kU/L)	27.8	0.82 (0.75 to 0.89)	< 0.001	0.62 (0.56 to 0.68)	< 0.001

GM, Geometric mean.



Online table 5. Net change in IgE sensitisation (>0.70 kU<sub>A</sub>/L) to house dust mite, grass, and cat over 20 years, by birth cohort.

	1964-1973 (N = 736) Net change (95% CI)			1954-1963 (N = 1314) Net change (95% CI)			1944-1953 (N = 1156) Net change (95% CI)		
	Prevalence or GM	Net change (95% CI)		Prevalence or GM	Net change (95% CI)		Prevalence or GM	Net change (95% CI)	
	ECRHS I	ECRHS II vs I	ECRHS III vs I	ECRHS I	ECRHS II vs I	ECRHS III vs I	ECRHS I	ECRHS II vs I	ECRHS III vs I
House dust mite	15.0	0.3 (-1.9 to 2.4)	-1.5 (-4.2 to 1.2)	14.1	-0.9 (-2.6 to 0.8)	-4.4 (-6.4 to -2.4)	9.9	-1.3 (-2.7 to 0.0)	-2.7 (-4.5 to -0.9)
Grass	18.2	1.7 (-0.8 to 4.2)	-0.7 (-3.7 to 2.4)	13.8	0.1 (-1.6 to 1.7)	-2.2 (-4.3 to -0.2)	11.4	-1.6 (-3.2 to 0.0)	-3.5 (-5.3 to -1.7)
Cat	7.7	1.0 (-1.2 to 3.1)	-0.1 (-2.3 to 2.1)	5.8	-0.3 (-1.5 to 0.9)	-0.8 (-2.2 to 0.7)	5.9	-0.3 (-1.6 to 1.0)	-2.3 (-3.6 to -1.0)
House dust mite or grass or cat	29.5	1.2 (-1.7 to 4.1)	-2.3 (-6.0 to 1.4)	24.1	-0.6 (-2.7 to 1.6)	-5.4 (-7.9 to -2.9)	19.6	-2.2 (-4.2 to -0.3)	-5.4 (-7.8 to -3.1)





## Online figure 2



Geometric mean ratio of total IgE over 20 years of follow up (ECRHS III vs I), with 95% CI and N of subjects